Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

BACKGROUND: Treatment options for adolescents with moderate-to-severe atopic dermatitis (AD) are limited. Oral corticosteroid therapies are used to treat children and adolescents with moderate-to-severe AD; however, long-term use is not recommended because of potential growth impairment. Upadacitini...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Toshiaki, Sasaki, Takuya, Ikeda, Kimitoshi, Liu, Jianzhong, Tenorio, Allan R., Ohya, Yukihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478921/
https://www.ncbi.nlm.nih.gov/pubmed/36185549
http://dx.doi.org/10.1016/j.waojou.2022.100678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478921/
https://www.ncbi.nlm.nih.gov/pubmed/36185549
http://dx.doi.org/10.1016/j.waojou.2022.100678

Ejemplares similares